Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron.
Benlarbi M, Laroche G, Fink C, Fu K, Mulloy RP, Phan A, Ariana A, Stewart CM, Prévost J, Beaudoin-Bussières G, Daniel R, Bo Y, El Ferri O, Yockell-Lelièvre J, Stanford WL, Giguère PM, Mubareka S, Finzi A, Dekaban GA, Dikeakos JD, Côté M. Benlarbi M, et al. Among authors: bo y. iScience. 2022 Nov 18;25(11):105316. doi: 10.1016/j.isci.2022.105316. Epub 2022 Oct 10. iScience. 2022. PMID: 36254158 Free PMC article.
Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments.
Stewart CM, Phan A, Bo Y, LeBlond ND, Smith TKT, Laroche G, Giguère PM, Fullerton MD, Pelchat M, Kobasa D, Côté M. Stewart CM, et al. Among authors: bo y. PLoS Pathog. 2021 Jan 29;17(1):e1009275. doi: 10.1371/journal.ppat.1009275. eCollection 2021 Jan. PLoS Pathog. 2021. PMID: 33513206 Free PMC article.
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.
Li W, Chen Y, Prévost J, Ullah I, Lu M, Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP, Goyette G, Chaterjee D, Ding S, Tolbert WD, Grunst MW, Bo Y, Zhang S, Richard J, Zhou F, Huang RK, Esser L, Zeher A, Côté M, Kumar P, Sodroski J, Xia D, Uchil PD, Pazgier M, Finzi A, Mothes W. Li W, et al. Among authors: bo y. bioRxiv [Preprint]. 2021 Aug 3:2021.08.02.454546. doi: 10.1101/2021.08.02.454546. bioRxiv. 2021. Update in: Cell Rep. 2022 Jan 11;38(2):110210. doi: 10.1016/j.celrep.2021.110210 PMID: 34373853 Free PMC article. Updated. Preprint.
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, Finzi A. Tauzin A, et al. Among authors: bo y. Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5. doi: 10.1016/j.chom.2021.12.004. Epub 2021 Dec 3. Cell Host Microbe. 2022. PMID: 34953513 Free PMC article.
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.
Li W, Chen Y, Prévost J, Ullah I, Lu M, Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP, Goyette G, Chaterjee D, Ding S, Tolbert WD, Grunst MW, Bo Y, Zhang S, Richard J, Zhou F, Huang RK, Esser L, Zeher A, Côté M, Kumar P, Sodroski J, Xia D, Uchil PD, Pazgier M, Finzi A, Mothes W. Li W, et al. Among authors: bo y. Cell Rep. 2022 Jan 11;38(2):110210. doi: 10.1016/j.celrep.2021.110210. Epub 2021 Dec 15. Cell Rep. 2022. PMID: 34971573 Free PMC article.
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Chatterjee D, Tauzin A, Laumaea A, Gong SY, Bo Y, Guilbault A, Goyette G, Bourassa C, Gendron-Lepage G, Medjahed H, Richard J, Moreira S, Côté M, Finzi A. Chatterjee D, et al. Among authors: bo y. Viruses. 2022 Jan 14;14(1):144. doi: 10.3390/v14010144. Viruses. 2022. PMID: 35062348 Free PMC article.
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Chatterjee D, Tauzin A, Marchitto L, Gong SY, Boutin M, Bourassa C, Beaudoin-Bussières G, Bo Y, Ding S, Laumaea A, Vézina D, Perreault J, Gokool L, Morrisseau C, Arlotto P, Fournier É, Guilbault A, Delisle B, Levade I, Goyette G, Gendron-Lepage G, Medjahed H, De Serres G, Tremblay C, Martel-Laferrière V, Kaufmann DE, Bazin R, Prévost J, Moreira S, Richard J, Côté M, Finzi A. Chatterjee D, et al. Among authors: bo y. Cell Rep. 2022 Mar 1;38(9):110429. doi: 10.1016/j.celrep.2022.110429. Epub 2022 Feb 8. Cell Rep. 2022. PMID: 35216664 Free PMC article.
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.
Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, Finzi A. Tauzin A, et al. Among authors: bo y. Cell Rep. 2022 Oct 25;41(4):111554. doi: 10.1016/j.celrep.2022.111554. Epub 2022 Oct 5. Cell Rep. 2022. PMID: 36244343 Free PMC article.
615 results